Abstract
Purpose
To report the outcomes of primary transpupillary thermotherapy (TTT) for choroidal melanomas.
Methods
A total of 78 patients were treated with TTT. Tumor thickness was up to 3.6 mm (mean 2.05 mm), follow-up 2.5–108 months (mean, 32.8 months). The main outcome measures were local control, enucleations, tumor recurrences, complications, and visual acuity. The predictors of treatment failures were analyzed.
Results
A total of 51 tumors regressed completely, and 20 incompletely. Out of 7 patients without response, 2 had enucleation, and 5 had Ru-106 irradiation. Recurrences after primary response were observed in 10 patients in 7–54 months (mean 23.4), 8 of them after incomplete regression. Six recurrences were successfully treated with additional TTT, and 4 with brachytherapy There were no metastases or deaths. Logistic regression showed the main predictive factors for TTT failure to be tumor height (OR=6.85; 95% 01=1.2–38.1; p=0.02), basal diameter (OR=22.85; 95% 01=3.6–144.7; p=0.0003), amelanotic pigmentation (for primary failure, OR=9.18; 95% Cl=1.7–49.2; p=0.008), high maximum systolic velocity (for primary failure, OR=13.6; 95% 01=2.3–81.7; p=0.003), subretinal fluid (OR=11.04; 95% 01=1.2–100.4; p=0.03), and incomplete regression (OR=30.62; 95% 01=6.0–156.4; p=0.00001). Receiver operating characteristic analysis showed the following cutoff levels: for tumor height 3.0 mm, for basal diameter 10.2 mm, for maximum systolic velocity 11.7 cm/s. Kaplan-Meier analysis of negative results was fulfilled in all treated patients and in patients without negative predictors. Mean visual acuity before TTT was 0.65, and after treatment 0.58. A total of 23% of patients had increased visual acuity, 42% had decreased acuity, and there was no change in 35%.
Conclusions
TTT is an investigative treatment for choroidal melanomas. TTT needs careful selection of patients, based on consideration of predictive factors and functional perspectives.
Get full access to this article
View all access options for this article.